Growth Equity Opportunities Fund IV, LLC 13D and 13G filings for Addex Therapeutics Ltd:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-04-10 4:06 pm Unchanged |
2023-04-04 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 8.500% |
0 (Unchanged) |
Filing |
| 2022-11-28 3:19 pm Unchanged |
2022-11-22 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 9.700% |
0 (Unchanged) |
Filing |
| 2022-08-23 5:18 pm Unchanged |
2022-07-26 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 15.100% |
0 (Unchanged) |
Filing |
| 2022-01-10 1:15 pm Unchanged |
2021-12-16 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 20.400% |
0 (Unchanged) |
Filing |
| 2021-01-21 6:47 pm Purchase |
2021-01-11 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 21.500% |
385,230 (New Position) |
Filing |